- Title: Sexual dysfunction among Nigerian women living with HIV infection 1
- Oliver Ezechi^{1,2}, Folahanmi Akinsolu^{1,2}, Tititola Gbajabiamila¹, Ifeoma Idigbe^{1&}, Paschal 2
- Ezeobi^{1,2}, Adesola Musa^{1,2}, Agatha Wapmuk¹ 3
- 5 ¹Center for Reproduction and Population Health Studies, Department of Clinical Sciences, Nigerian
- 6 Institute of Medical Research, Yaba, Lagos State, Nigeria
- ²Department of Public Health, Faculty of Basic Medical and Health Sciences, Lead City University,
- Ibadan, Oyo State, Nigeria 8
- 9 *Corresponding author

11

12

14

15

16

- E-mail: folahanmi.tomiwa@gmail.com: Akinsolu.folahanmi@lcu.edu.ng 10
 - ☐ These authors contributed equally to this work.
- &These authors also contributed equally to this work. 13

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity.

It is made available under a CC-BY 4.0 International license .

ABSTRACT

17

18

2627

28

31

32

34

35

37

3940

41

43

46

47

Introduction

- 19 Sexual dysfunction in women with HIV is a necessary but understudied aspect of HIV complications in women
- 20 living with HIV. This study reports the prevalence, pattern, and risk factors for sexual dysfunction in women
- 21 living with HIV in southwest Nigeria.

22 Methods

- 23 A validated Female Sexual Function Index was used to determine sexual dysfunction in a cross-sectional study
- design involving 2926 adult women living with HIV in a large, publicly funded tertiary HIV treatment centre
- 25 in Lagos, Nigeria. A score of less than 26.5 indicated sexual dysfunction. Multivariate logistic regression
 - analysis was performed to identify risk factors for sexual dysfunction. P<0.05 was considered statistically
 - significant at a 95% confidence interval (CI).

Results

- 29 The prevalence of sexual dysfunction was 71.4%. The types of dysfunctions detected included disorder of
- 30 desire (76.8%), sexual arousal (66.0%), orgasm (50.0%), pain (47.2%), lubrication (47.2%), and satisfaction
 - (38.8%). Multivariate analysis showed that menopause (aOR: 2.0; 1.4 4.1), PHQ score of 10 and above
 - (aOR: 2.3; 1.7 3.2), co-morbid medical conditions (aOR: 1.8; 1.4 2.7), use of protease inhibitor-based
- antiretroviral therapy (aOR: 1.3; 1.2 2.1) and non-disclosure of HIV status (aOR: 0.7; 0.6-0.8) were factors
 - associated with sexual dysfunction.

Conclusions

- 36 Sexual dysfunction is common among Nigerian women living with HIV. Menopause, use of protease
 - inhibitor-based regimens, PHQ score of at least 10, co-morbid medical condition, and non-disclosure of HIV
- 38 status were associated with sexual dysfunction. National HIV programmes, in addition to incorporating
 - screening and management of sexual dysfunction in the guidelines, should sensitise and train health workers
 - on the detection and treatment of sexual dysfunction.
- 42 Abstract word count: 257
- 44 **Keywords:** Sexual dysfunction, female sexual dysfunction, Female Sexual Function Index, human
- 45 immunodeficiency virus, antiretroviral therapy, protease inhibitor, Nigeria

Introduction

48

56

60

63

67

68

69

71

- The introduction and increased access to antiretroviral therapy have changed human immunodeficiency virus 49
- (HIV) infection, a disease once considered a death sentence, to a chronic, manageable health condition. The 50
- widespread availability and use of potent combination antiretroviral therapy have dramatically reduced the 51
- morbidity and mortality of HIV infection globally and in sub-Saharan Africa.⁴ 52
- The marked improvement in the clinical outcome of HIV infection has prompted a paradigm shift in the 53
- measure of HIV treatment success from mortality to quality of life.⁵ Ouality of life is a multidimensional 54
- construct defined as a subjective evaluation of one's functioning and well-being. It is affected not only by 55
 - individual lifestyle but also by social norms, cultural practices, and belief systems, so it varies among regions
- and population groups.^{6,7} 57
- Numerous studies in sub-Saharan Africa have examined the health-related quality of life in HIV-infected 58
- 59 persons, with most studies emphasizing the physical, mental, and social aspects of quality of life while leaving
 - out the sexual function component.⁷⁻²¹ The few studies that addressed some aspect of sexual functioning were
- either limited by sample size or did not use a globally accepted and validated tool, such as Female Sexual 61
- Function Index questionnaire, in conducting their study. 19-21 Few studies focused on sexual dysfunction among 62
 - HIV-positive women, even though a high prevalence of sexual dysfunction in persons living with HIV/AIDS
- has been reported .22-24 64
- There are many reasons to expect an increase in sexual dysfunction in persons living with HIV infections, 65
- with psychological, endocrine, and neurologic factors being the most important. ²⁵⁻²⁷ However, proving a link 66
 - between these factors and sexual dysfunction is difficult, as many of the conditions commonly seen within the
 - HIV context, such as depression, peripheral neuropathy, and hypogonadism, are associated with sexual
 - dysfunction in other settings also.^{25,26} Furthermore, establishing associations with drugs or classes of drugs is
- difficult, as these agents often are used in combinations, and some of the drug-related toxicities persist even 70
 - after replacement with another drug, leading to wrong attribution. 25,28,29
- Whereas several studies have evaluated sexual dysfunction in HIV-positive men,³⁰ but few studies have 72
- examined the sexual function of women living with HIV/AIDS.²⁵ In Nigeria, despite its high HIV burden, an 73
- 74 extensive literature search has revealed only three studies reporting on sexual dysfunction among HIV-positive
- women, ²²⁻²⁴ despite several studies on sexual dysfunction among women with chronic diseases, pregnancy, 75
- 76 infertility, diabetes mellitus, or hypertension.³¹⁻³⁶ This study was conducted to determine the prevalence,
- pattern, and risk factors of sexual dysfunction among HIV-positive women in Lagos, Southwest Nigeria. 77

Methods

80

81

82

83

84

85

86

87

88

89

90

91

92 93

94

95

96

97

98 99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122 123

124

125

126

Study setting, design, sample size, and sampling

This cross-sectional study was conducted between January 2019 and December 2020 at a large publicly funded tertiary comprehensive HIV treatment centre in a cosmopolitan city in southwestern Nigeria. The centre has cumulatively enrolled over 25.000 HIV-positive clients, 65% of whom are women. To participate in the study. the women had to be older than 18 years and proven HIV-positive for more than six months. The minimal sample size for the study was calculated with Raosoft online sample size calculator (http://www.raosoft.com/samplesize.html),38 with a 99% CI, 2.5% margin of error, and assumed prevalence of sexual dysfunction among HIV positive to be 61.0%.²¹ A total sample size of 2916 HIV-positive women was required, assuming a 30% non-response rate. A total of 3205 respondents randomly selected from the clinic attendance register were recruited for the study.

HIV-positive women attending the treatment centre were approached for the interview after selection from the lists of attendees, using a proportionate stratified sampling method. This method enabled the generalization of the study's findings to the women in the clinic. Each clinic's two-patient categories, drug refill; and 3-6 monthly physician consults, were considered a homogenous population. These two categories were often in the ratio of 2:1 at each of the three clinic days a week. The daily list of clinic attendees was categorized into the two groups above, each serving as a frame. Respondents were then selected from the frames by simple random sampling, using the ratio of 2:1. Those who accepted to participate and signed an informed consent form were recruited.

Study tools, data collection, and statistical analysis

A self-administered structured data collection form consisting of three sections. (A) Demographic characteristics, (B) Patient Depression Question (PHQ), and (C) Female Sexual Function Index, were used to collect data for the study. Low-literate respondents were assisted in completing the forms by trained research assistants. The respondents' hospital numbers were written on each form to enable linkage to respondents' medical records. The demographic section of the form captured respondents' socioeconomic characteristics, medical and reproductive history, current and previous antiretroviral treatment, and recent laboratory results (CD4 cell count and viral load). The second section was the PHQ-9, ^{39,40}, a 9-item self-report questionnaire in which participants rated their feelings during the previous two weeks. Each question is scored 0 to 3 (0 = notat all, 1 = several days, 2 = more than half the days, and 3 = nearly every day), resulting in a 0 to 27. The nine items reflect the DSM-IV criteria for major depressive disorders. For this study, a score of 10 and above was considered depression. The last section is the Female Sexual Function Index (FSFI)^{41,42}, a 19-item self-report instrument that scores six domains of sexual function in women in the previous four weeks. These domains include desire (two items, questions 1–2), arousal (four items, questions 3–6), lubrication (four items, questions 7–10), orgasm (three items, questions 11–13), satisfaction (three items, questions 14–16), and pain (three items, questions 17–19). The total FSFI score was determined by the sum of the six domains, with the minimum and maximum scores possibly varying from 2.0 to 36.0. A score greater than 26.5 denoted a low level of sexual dysfunction, and a score of 26.5 or less indicated sexual dysfunction. Likewise, scores on desire, arousal, lubrication, orgasm, satisfaction, and pain, which are ≤ 3.6 (score range, 1.2–6), ≤ 3.9 (score range, 0-6), ≤ 3.6 (score range, 0-6), ≤ 3.6 (score range, 0-6), ≤ 3.6 (score range, 0-6) and ≤ 4.4 (score range, 0-6), respectively; all indicate sexual dysfunction related to subdimensions. ^{32,41-43} The FSFI has been validated on a clinically diagnosed sample of women with female sexual disorders. 44 In our setting, 43 however, because the study was in a specific population, the validity and reliability in the study population were confirmed with 100 HIV-positive women. A Cronbach's alpha score of 0.85 was obtained, indicating good reliability.

The study results were presented as means and percentages. The total FSFI scores were categorized into dichotomous variables (normal sexual function and sexual dysfunction) using a cut-off point of 26.5.42,43

Frequency distributions were generated, and univariate analysis using relevant statistics was performed to identify factors associated with sexual dysfunction. Multivariate logistic regression was used to identify independent risk factors for sexual dysfunction while controlling for potential confounders, including the severity of HIV disease measured by CD4 count and HIV viral load, time since HIV diagnosis, duration of antiretroviral drug use. PHO-9 score of > 10. co-morbid state, education, employment status, marital status. age, and menopausal state. Variables were entered into the model if their P value on univariate analysis was < 0.25 or less. The variable with the strongest association in the univariate model was estimated first, followed by others in descending order. In the analysis, the comparison group consisted of those with an FSFI score of > 26.5 (no sexual dysfunction). P < 0.05 was considered statistically significant. Odds Ratios (OR) and 95% Confidence Intervals (CI) for the OR were also calculated. All analyses were performed with SPSS statistical software package version 23.0 for Windows, SPSS Inc., Chicago, IL, USA.

Ethical considerations

127

128

129

130

131

132

133

134

135

136

137 138

139

140

141

142

143

144 145 146 Ethical approval for the study was obtained from the Institutional Review Board of the Nigerian Institute of Medical Research, Lagos, Nigeria. Written informed consent was obtained from participants after the study objectives and methods were explained to the participants. The participants were assured of the confidentiality and anonymity of their data during and after the study. The women who declined to consent to participate in the study were provided their routine care but excluded from participation in the study.

Results

147

148 149

150 151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167 168

169

170

171 172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191 192 3205 HIV-positive women were approached to participate in the study, of which 3009 (93.9%) accepted and were given the study forms or interviewed by research assistants. The study forms 2926 (91.3%) women in a stable monogamous and heterosexual relationship were completed and retrieved.

The sociodemographic characteristics of the HIV-positive women in the study are shown in Table 1. Most of

the women were less than 35 years of age (68.5%), married (53.1%), Christian (73.2%), working (59.5%),

Sociodemographic and HIV-related characteristics of the respondents

and from one of the three major Nigerian ethnic groups (75.8%). 78.5% had completed at least a secondary education. Four hundred and thirty-two (14.8%) HIV-positive women were postmenopausal. HIV-related characteristics of the respondents are shown in Table 2, and the time elapsed since HIV diagnosis ranged from 6 to 204 months, with a median of 102 ± 41 months. In most respondents (56.5%), HIV diagnosis had been made within 120 months. Most of the women had CD4 cell counts above 200 cells/mm³ (73.6%). not detectable HIV viral load (62.3%), HIV positive partners (56.5%) and had disclosed their HIV status to their partner (66.3%). Of the 2926 respondents in the study, 2051 (70.1%) received a non-nucleoside reverse transcriptase inhibitor-based regimen, and 874 (21.9%) received a protease inhibitor-based regimen. The duration of antiretroviral therapy (ART) among the respondents ranged from 6 to 204 months, with a median of 101± 31 months. Whereas (1743: 59.6%) of the respondents treated with ART have been receiving it for less than 96 months, the remaining 1182 (52.6%) had been on receiving ART for 95 months or more. At the time of the interview, 509 (20.2%) women had opportunistic infections, and 564 (21.9%) had one or more co-

Respondents' PHQ-9 total score

morbid medical conditions.

The total score ranged from 0-25, with a mean of 5.6 ± 2.3 . Most respondents had PHO-9 scores of less than 10 (85.3%), and the remaining respondents (14.7%) had PHQ-9 scores of 10 and above. Only twenty-five respondents (0.8%) had a total score of 20 and above.

Sexual dysfunction among the respondents

Of the 2926 women with complete questionnaires, 2089 had FSFI score ≤ 26.6 or a sexual dysfunction rate of 71.4% (CI: 68.4 - 75.3). The distribution of respondents with sexual dysfunction in each of the six domains of sexual function is shown in Table 4. The percentage of sexual dysfunction in the domains ranged from 38.8% in the satisfaction domain to 76.8% in the desire domain. At least half of the respondents had dysfunction in desire (76.8%), arousal (66.0%), and orgasm (50.0%) domains. The proportion of respondents with dysfunction in pain, lubrication, and satisfaction domain was 47.2%, 47.2%, and 38.8%, respectively.

Risk factors for sexual dysfunction among the cohort

Table 5 shows the relationship between the women's sociodemographic characteristics, co-morbid conditions, HIV characteristics, and sexual dysfunction. On univariate analysis, a significant association was found between women aged 35 years and above (cOR: 1.4; 1.0 - 1.8), marital status (cOR: 0.5; 0.4 - 0.7), PHO Score of 10 and above (cOR: 2.5; 1.6-4.0), postmenopausal state (cOR: 2.5; 1.1-5.6), co-morbid medical condition (cOR: 1.8: 1.1 - 3.0) and SD. No statistically significant association was found between educational status (p=0.51), religion (p=0.47), employment status (p=0.31), and sexual dysfunction. The relationship between HIV-related factors and sexual dysfunction is summarized in Table 6. A statistically significant association was also found between HIV status disclosure (cOR:0.7; 0.6 - 0.97), use of protease inhibitor-based antiretroviral drug regimen (cOR: 1.6; 1.1 - 2.4), duration of antiretroviral therapy of less than 96 months (cOR:1.5:1.1-2.1), the presence of opportunistic infection (cOR:1.6(1.1-2.4)) and sexual dysfunction. Time elapsed since HIV diagnosis (p=0.18), CD4 count (p=0.8), HIV viral load (p=0.1), and partners' positive HIV status (p=0.6) have no significant association with sexual dysfunction.

194

195

196 197

198 199 200 After adjustment for potential confounding variables of age, menopausal age, duration of HIV infection, antiretroviral drug regimen, HIV status disclosure, presence of opportunistic infection, PHQ score, and comorbid medical conditions in the multivariate logistic regression model, sexual dysfunction in HIV-positive women had an independent statistically significant association with the postmenopausal state (aOR: 2.0; 1.4 -4.1), PHQ score of 10 and above (aOR: 2.3; 1.7 – 3.2), co-morbid medical conditions (aOR: 1.8; 1.4 – 2.7), use of protease-based regimen (aOR: 1.3; 1.2 - 2.1), and HIV status disclosure (aOR: 0.7; 0.6-0.8).

Discussion

201

202

203

204

205

206

207

208

209

210

211

212 213

214

215

216

217 218

219

220

221

222 223

224

225

226 227

228

229

230

231

232

233

234

235

236

237

238 239

240

241

242

243

244

245 246

247

Whereas several studies reporting the prevalence and risk factors for sexual dysfunction in the general population and select medical conditions abound, 40-43 data on sexual dysfunction among HIV-positive women is limited.²¹ In Nigeria, with the second largest HIV burden globally, the situation is more dire, as only three publications have reported on sexual dysfunction among HIV-positive women.²³⁻²⁵ The three Nigerian studies were conducted in a predominantly Muslim population with a relatively small sample size, making the findings difficult to generalize. In this study, we determined the prevalence, pattern, and risk factors for sexual dysfunction using information obtained from a large population of HIV-positive women residing in a cosmopolitan city that reflected sociocultural diversity who had been receiving antiretroviral therapy for much longer. The larger sample size also made it possible to conduct subgroup analyses that are powered to make generalization easier. Information obtained in the study will assist in identifying HIV-positive women with sexual dysfunction within the country, within our subregion, and elsewhere to provide adequate care.

The sexual dysfunction rate of 71.4% in this study is within 61.0 - 89.2% reported in Nigerian studies. ²³⁻²⁵ It is, however, higher than the rates reported among HIV-positive women in India⁴⁵ and Europe. ^{46,47} Although female sexual dysfunction is a widespread health condition, controversy exists regarding the burden of female sexual dysfunction; vast differences are reported within and between countries. The differences may reflect medical and psychological factors, especially in socioeconomic; cultural; and ethnic differences; the definition used for each type of dysfunction; the type of study tool, the method of data collection; samples; and characteristics of populations studied. ^{23-25, 45-49} In addition, the observed higher prevalence in our setting and sub-Saharan Africa may be due to cultural differences in the settings or reluctance of women in the sub-Saharan region to talk openly about sex and seek solutions for their sexual concerns. 21,23-25, 45-49 The various explanations for the observed differences have also made generalization and comparison of studies challenging. This study used a validated and standardized tool and a specific population group to ensure generalization to our population group and context. This study confirmed that HIV infection is associated with high sexual dysfunction and thus deserves close attention. ^{23-25, 45-49}

As expected, the frequency of abnormality in specific sexual function domains is higher in the HIV-positive population studied than in the general population, but it is like the frequency reported in other studies among HIV-positive women. ^{25,45-47,50} Previous studies reported an association between HIV infection and poor quality of life resulting from physical, psychological, or emotional factors. 6-10 Medical conditions, including HIV infection, reduce the quality of life and thus impact sexual function.^{20,21} Findings in this study support this assertion, as a co-morbid medical condition (aOR: 1.8; 1.1 - 3.0) and patients' health questionnaire scores of at least 10 (aOR: 2.3; 1.7 - 3.2) retained independent statistically significant association with sexual dysfunction after controlling for potential confounding variables. More than half of the respondents in this study had dysfunction in at least three specific sex domains: desire (76.8%), arousal (66.0%), and orgasm (50.0%). A large proportion also had dysfunction in the remaining three sexual function domains: pain (47.2%), lubrication (47.2%), and satisfaction (38.8%) domain. These findings are similar to previous studies conducted in Nigeria and other African countries among HIV-positive women, in which the most prevalent type of sexual dysfunction was in the domain of desire, whereas the least was in the domain of pain. 21-25,50 The above finding, however, is higher than the findings of studies among the general population, but the distribution of degrees of dysfunction in the various domains was like the findings in women living with HIV. 30,51-55 Across most studies, dysfunction in the desire domain was the commonest, and dysfunction in the pain domain was the least common, as found in this study. Castelo-Branco et al., ⁵⁴ in their study among healthy women living in Santiago de Chile, found desire disorder (38.0%) the most common, followed by arousal disorder (32.0%), pain disorder (33%), and orgasm disorder (25.0%). In a study by Kadri and colleagues⁵⁵ among women living in Morocco, desire disorder was reported by 18%, orgasm disorder by 12%, arousal

disorder by 8%, and pain disorder by 8%. The inference that can be made from the above is that while the severity of specific domain dysfunction may be worse in HIV-positive women, their distribution and pattern of occurrence are like those in HIV-positive and HIV-negative women. 21,23-25, 54,55

248

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271 272

273 274

275

276

277

278 279

280

281

282

283

284

285

286

287 288

289

290

291

The present study found that the postmenopausal state (aOR: 2.5), PHQ score of at least 10 (aOR: 2.5), opportunistic infection (aOR:1.4), co-morbid medical condition (aOR: 1.8), use of protease-based antiretroviral regimen (aOR: 1.3), and HIV status disclosure (aOR: 0.7) were independently associated with sexual dysfunction in women living with HIV infection. A menopausal state was also found as a risk factor for sexual dysfunction in other studies involving women with known HIV status and the general population. 21,56,57 It is possible that changes in blood hormonal levels with age in women account for their decline in sexual functioning in menopause. ^{21,50,58} These changes occur in all women, not only those HIVpositive. The presence of opportunistic infection and co-morbid medical conditions, such as hypertension and diabetes, were also identified as risk factors for sexual dysfunction among women in this study. A common opportunistic infection among the cohort in our clinic is tuberculosis.⁵⁹ Available literature has reported that active tuberculosis disrupts sexual function in male and female patients. Tuberculosis usually disturbs the mental and physical well-being of those infected. Its chronic nature, long isolation period, and enormous pill burden taken over a long period may lead to sexual dysfunction. Tuberculosis of the female genital tract is one of the leading causes of reproductive dysfunction as well.⁶⁰ Sexual dysfunction is frequently a challenge in patients with other medical diseases, such as hypertension and diabetes, and it may occur either as a side effect of medications or as a component of the dysmetabolic syndrome of high blood pressure. 30,33 Hypertension and diabetes are two common medical comorbidities in our environment among the HIV patient population, 61 and 61.0 - 88% of patients with these diseases have sexual dysfunction; 21,25,33,62 thus, it is not surprising that co-morbid conditions retained an independent statistical association with sexual dysfunction even after controlling for other possible confounders. This association was also found in other studies in our environment. ^{21,30,33} The use of antiretroviral therapy has been shown to ameliorate sexual dysfunction in several studies²¹; however, we could not access this variable in our study, as it is now unethical not to start HIV-positive patients on antiretroviral therapy; the studies that reported the association between sexual dysfunction and the use of antiretroviral therapy were conducted before the treat-all policy was instituted. In the present study, we could only assess if there is an association between the type of antiretroviral therapy regimen and sexual dysfunction; this study, like some other previous studies, 63,64 found that the use of protease inhibitors was an independent risk factor for sexual dysfunction in HIV- positive women. Schrooten et al., ⁶³, in their study in 10 European countries of HIV-positive patients receiving antiretroviral agents, found a decrease in sexual interest and potency among those receiving protease inhibitors compared with protease inhibitor-naive patients.

In this study, non-disclosure of HIV status was also an independent risk factor for sexual dysfunction. This finding is consistent with the findings of previous studies. 21,23 In women with HIV, sexual dysfunction is complex because of contextual sociocultural issues, financial challenges, depression, caregiving duties, and challenges of status disclosure. 21-23,50,65 These issues are most likely to affect sexual function. However, the most challenging is the fear of disclosure of HIV status (which is known to result in violence) and the associated guilt, especially if the partner is HIV-negative or of unknown status. It is, therefore, not surprising that non-disclosure was found to be a risk factor for sexual dysfunction. The guilt of infecting an HIV-negative partner or the fear of violence following disclosure has the potential to impact the sexual functioning of the women involved negatively.

Strengths and limitations

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

Our study has strengths: It was conducted in an HIV-endemic country with a large sample size using an internationally accepted and validated tool. The study was also conducted in a cosmopolitan city with sociocultural, religious, and economic diversity mimicking what is present nationally. However, the study also has limitations: its cross-sectional design did not allow for the assessment of the temporal association between sexual dysfunction and various factors studied. The study was conducted in a single city and clinic, though of more than 20 million population and over 20,000 patients; this makes it difficult to generalize to all women living with HIV in Nigeria. FSFI, the study tool, has been criticized for considering only penetrative sex as the single requirement for sexual well-being. Finally, about 10% of eligible patients who were approached declined to participate, failed to return the data collection form, or returned incompletely answered forms: although the rate was relatively low, it could still have affected the generalizability of the study results.

Conclusions

Sexual dysfunction is a significant public health challenge among HIV-positive women in Nigeria and sub-Saharan Africa, where HIV is endemic. The sexual dysfunction rate of 71.4% confirms that it is a significant challenge in our setting. Sexual dysfunction in the six domains ranged from 38.8% in the satisfaction domain to 76.8% in the desire domain. Six factors are significantly associated with sexual dysfunction; menopausal state, PHO score of 10 and above, opportunistic infection, co-morbid medical condition, use of protease-based antiretroviral regimen, and non-disclosure of HIV status. There is a need to sensitize and train healthcare workers to assess for sexual challenges during routine programmatic consultations. The national HIV programs should, as a matter of urgency, include screening and treatment of sexual dysfunctions among HIVpositive women in the country's treatment guidelines.

References

313

315

316

317

319 320

321

322 323

324 325

326

327

328

329

330

331 332

333

334 335

336

337

338

339

340

341

342

343

344 345

346

347 348

349

350

351

352

353 354

355

- 1. McGee C. The Continuing Impact of HIV/AIDS on Development in Africa: A Systematic Analysis Using the Political Systems and Contagious Disease Theories. InAfrica and Globalization 2020 (pp. 171-187). Palgrave Macmillan, Cham.
- Giguère K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, Jahn A, Wanyeki I, Mbofana F, Bakiono F, Mahy M. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data. The Lancet HIV. 2021 May 1;8(5):e284-93.
- Ukaegbu E, Alibekova R, Ali S, Crape B, Issanov A. Trends of HIV/AIDS knowledge and attitudes among Nigerian women between 2007 and 2017 using Multiple Indicator Cluster Survey data. BMC Public Health. 2022 Dec;22(1):1-2.
- Mojola SA, Angotti N, Denardo D, Schatz E, Xavier Gómez Olivé F. The end of AIDS? HIV and the new landscape of illness in rural South Africa. Global Public Health. 2022 Jan 2;17(1):13-25.
- Rintamaki L, Kosenko K, Hogan T, Scott AM, Dobmeier C, Tingue E, Peek D. The role of stigma management in HIV treatment adherence. International journal of environmental research and public health. 2019 Dec;16(24):5003.
- 6. Alexander G, Thomas RA. Health-Related Quality of Life in HIV-positive Women on Long-Term Antiretroviral Therapy—A Study from Bangalore, South India. World Journal of AIDS. 2022 Apr 11;12(2):97-110.
- Rasoolinajad M, Abedinia N, Noorbala AA, Mohraz M, Badie BM, Hamad A, Sahebi L. Relationship among HIV-related stigma, mental health and quality of life for HIV-positive patients in Tehran. AIDS and Behavior. 2018 Dec;22(12):3773-82.
- Karugaba G, Thupayagale-Tshweneagae G, Moleki MM, Mabikwa OV, Matshaba M. Determinants of health-related quality of life in young adults living with perinatally acquired HIV infection in Botswana. Southern African Journal of HIV Medicine. 2022 Apr 29;23(1):10.
- 9. Abebe Weldsilase Y, Likka MH, Wakayo T, Gerbaba M. Health-related quality of life and associated factors among women on antiretroviral therapy in health facilities of Jimma Town, Southwest Ethiopia. Advances in Public Health. 2018 Sep 16;2018.
- 10. Osei-Yeboah J, Owiredu WK, Norgbe GK, Lokpo SY, Obirikorang C, Alote Allotey E, Gameli Deku J, Akomanin Asiamah E, Manaphraim NY, Senyo Kwasi Nyamadi P, Yiadom Boakye E. Quality of life of people living with HIV/AIDS in the Ho Municipality, Ghana: a cross-sectional study. AIDS research and treatment. 2017 Oct 24;2017.
- 11. Alemayehu M, Wubshet M, Mesfin N, Tamiru A, Gebayehu A. Health-related quality of life of HIV infected adults with and without Visceral Leishmaniasis in Northwest Ethiopia. Health and quality of life outcomes. 2017 Dec;15(1):1-0.
- 12. Surur AS, Teni FS, Wale W, Ayalew Y, Tesfave B. Health related quality of life of HIV/AIDS patients on highly active antiretroviral therapy at a university referral hospital in Ethiopia. BMC health services research. 2017 Dec;17(1):1-8.
- 13. Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lönnmark E, Long L, Rosen S. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health and quality of life outcomes. 2019 Dec;17(1):1-5.
- 14. Kimera E, Vindevogel S, De Maeyer J, Reynaert D, Engelen AM, Nuwaha F, Rubaihayo J, Bilsen J. Challenges and support for quality of life of youths living with HIV/AIDS in schools and larger community in East Africa: a systematic review. Systematic Reviews. 2019 Dec;8(1):1-8.

15. Oladeji BD, Taiwo B, Mosuro O, Fayemiwo SA, Abiona T, Fought AJ, Robertson K, Ogunniyi A, Adewole IF. Suicidal behavior and associations with quality of life among HIV-infected patients in Ibadan, Nigeria. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2017 Jul;16(4):376-82.

358 359

360

361

362

363

364

365

366

367

368

369 370

371

372

373

374

375

376 377

379

380

381

382

383 384

385

386

387

388

389

390

391

392

393

394 395

396

397

398

399

400

401

402

- 16. Kanu NE. Tobin-West CI. Health-related quality of life of HIV patients with and without tuberculosis registered in a Tertiary Hospital in Port Harcourt, Nigeria. HIV & AIDS Review. International Journal of HIV-Related Problems. 2018 Jan 1;17(3):210-7.
- 17. Biambo AA. Adibe MO. Liman HM. Ukwe CV. Health-related quality of life of HIV-infected patients taking different antiretroviral regimens at a tertiary healthcare facility in northern Nigeria. Tropical Journal of Pharmaceutical Research. 2018 May 11;17(3):549-57.
- 18. Suleiman BA, Yahaya M, Olaniyan FA, Sule AG, Sufiyan MB. Determinants of health-related quality of life among human immunodeficiency virus positive (HIV-positive) patients at Ahmadu Bello University teaching hospital, Zaria, Nigeria-2015. BMC Public Health. 2020 Dec;20(1):1-9.
- 19. Onyekonwu CL, Onyeka TC, Brenda NC, Ijoma UN, Unaogu NN, Onwuekwe IO, Ugwumba F, Nwutobo CR, Nwachukwu CV. Chronic HIV infection and health related quality of life in resource poor settingsan assessment from South East Nigeria. African Health Sciences. 2020 Apr 20;20(1):102-13.
- 20. Mehta SD, Nordgren RK, Agingu W, Otieno F, Odongo W, Odhiambo F, Bailey RC. Sexual quality of life and association with HIV and sexually transmitted infections among a cohort of heterosexual couples in Kenya. The journal of sexual medicine. 2018 Oct 1;15(10):1446-55.
- 21. Huntingdon B. Muscat DM, de Wit J. Duracinsky M. Juraskova I. Factors associated with general sexual functioning and sexual satisfaction among people living with HIV: a systematic review. The Journal of Sex Research. 2020 Sep 1;57(7):824-35.
- 22. Bouhlel S, Derbel CH, Nakhli J, Bellazreg F, Meriem HB, Omezzine A, Ali BB. Sexual dysfunction in Tunisian patients living with HIV. Sexologies. 2017 Apr 1;26(2):e11-6.
- 23. Agaba PA, Meloni ST, Sule HM, Agaba EI, Idoko JA, Kanki PJ. Sexual dysfunction and its determinants among women infected with HIV. International Journal of Gynecology & Obstetrics. 2017 Jun;137(3):301-8.
- 24. Abiodun O, Sodeinde K, Adepoju A, Ohiaogu F, Mbonu F, Adelowo O, Bankole O. Sexual functioning, sexual distress, and well-being of sexually active adult women living with HIV: an HIV program-based cross-sectional study. Sexuality Research and Social Policy. 2020 Dec;17(4):558-67.
- 25. Oyedokun, A., Odeigah, L., Alabi, K., Adegunloye, O., Akujobi, H. (2014) Sexual dysfunction in HIVpositive women attending a tertiary health facility in North Central Nigeria. J AIDS Clin Res, 5: 398-398
- 26. Wilson TE, Jean-Louis G, Schwartz R, Golub ET, Cohen MH, Maki P, Greenblatt R, Massad LS, Robison E. Goparaju L. Lindau S. HIV infection and women's sexual functioning. J Acquir Immune Defic Syndr. 2010 Aug;54(4):360-7. doi: 10.1097/QAI.0b013e3181d01b14. PMID:
- 27. Shindel AW, Horberg MA, Smith JF, Breyer BN. Sexual dysfunction, HIV, and AIDS in men who have sex with men. AIDS Patient Care STDS. 2011 Jun;25(6):341-9. doi: 10.1089/apc.2011.0059. Epub 2011 Apr 18. PMID: 21501095; PMCID: PMC3101920.
- 28. Russell DB. Sexual function and dysfunction in older HIV-positive individuals. Sex Health. 2011 Dec;8(4):502-7. doi: 10.1071/SH11041. PMID: 22127035.
- 29. Scanavino Mde T. Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management. Adv Urol. 2011;2011:854792. doi: 10.1155/2011/854792. Epub 2011 Oct 20. PMID: 22046183; PMCID: PMC3199204.
- 30. Collazos J, Martínez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):322-6. doi: 10.1097/00126334-200211010-00008. PMID: 12439208.

- 31. De Vincentis S, Tartaro G, Rochira V, Santi D. HIV and Sexual Dysfunction in Men. J Clin Med. 2021 Mar 5:10(5):1088. doi: 10.3390/jcm10051088. PMID: 33807833; PMCID: PMC7961513.
- 32. Fajewonyomi BA, Orji EO, Adeyemo AO. Sexual dysfunction among female patients of reproductive age in a hospital setting in Nigeria. Journal of Health, Population and Nutrition. 2007 Mar 1:101-6.
- 33. Shaeer KZ, Osegbe DN, Siddiqui SH, Razzaque A, Glasser DB, Jaguste V. Prevalence of erectile dysfunction and its correlates among men attending primary care clinics in three countries: Pakistan, Egypt, and Nigeria. International journal of impotence research. 2003 Apr 1;15:S8-14.
- 34. Okeahialam BN, Obeka NC. Sexual dysfunction in female hypertensives. Journal of the National Medical Association. 2006 Apr;98(4):638.
- 35. Audu BM. Sexual dysfunction among infertile Nigerian women. Journal of Obstetrics and Gynaecology. 2002 Jan 1;22(6):655-7.
- 36. Orji EO, Ogunlola IO, Fasubaa OB. Sexuality among pregnant women in South West Nigeria. J Obstet Gynaecol. 2002;22:166-8.
- 37. Adenivi FA, Adeleve OJ, Adenivi YC. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. Current diabetes reviews. 2010 Jul 1;6(4):201-6.
- 38. Raosoft Incorporated. Raosoft Sample size calculator 2004. Available from URL:http://www.raosoft.com/samplesize.html.

405 406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425 426

427

428

429

430

431

432 433

434

435 436

437

438

439

440

441 442

443

444

- 39. Kroenke, K., Spitzer, R.L., Williams, J.B., 2001. The PHQ-9. Validity of a brief depression severity measure. J. Gen. Intern. Med. 16, 606-613.
- 40, Adewuya AO, Ola BA, Afolabi OO. Validity of the Patient Health Questionnaire (PHQ-9) as a screening tool for depression amongst Nigerian university students. Journal of Affective Disorders 2006; 96: 9-93
- 41, Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D'Agostino R. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy. 2000;26(2):191-208.
- 42. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cut-off scores. J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20. doi: 10.1080/00926230590475206. PMID: 15841702.
- 43. Nwagha UI, Oguanuo TC, Ekwuazi K, Olubobokun TO, Nwagha TU, Onyebuchi AK, Ezeonu PO, Nwadike K. Prevalence of sexual dysfunction among females in a university community in Enugu, Nigeria. Nigerian journal of clinical practice. 2014;17(6):791-6.
- 44. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003 Jan-Feb;29(1):39-46. doi: 10.1080/713847100. PMID: 12519665; PMCID: PMC2872178.
- 45. Muthiah B, Kallikadavil A, Shivaswamy R, Menon VB. The Study of Gonadal Hormonal Abnormalities and Sexual Dysfunction in HIV Positive Females: An Exploratory Study. Journal of Clinical and Diagnostic Research: JCDR. 2016;10(4):OC11-OC14. doi:10.7860/JCDR/2016/18992.7581.
- 46. Goggin K. Engelson ES. Rabkin JG. Kotler DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med 1998, 60:11-16
- 47. Florence E, Schrooten W, Dreezen C, Gordillo V, Schönnesson LN, Asboe D, Koitz G, Colebunders R, Eurosupport Study Group T. Prevalence and factors associated with sexual dysfunction among HIVpositive women in Europe. AIDS care. 2004 Jul 1;16(5):550-7.

- 48. Mezones-Holguin E, Cordova-Marcelo W, Lau-Chu-Fon F, Aguilar-Silva C, Morales-Cabrera J, Bolanos-Diaz R, et al. Association between sexual function and depression in sexually active, mid-aged, Peruvian women. Climacteric 2011;14:654-60.
- 49. Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. International Journal of Impotence Research. 2006 Jul 1;18(4):382-95.
- 50. Camara A, Tounkara TM, Delamou A, Baldé R, Leno NN, Kuotu GC, Touré A, Cissé M. Prevalence and risk factors of female sexual dysfunction among women infected with HIV in conakry. Clinical Epidemiology and Global Health. 2021 Oct 1;12:100828.
- 51. Turan V, Kopuz A, Ozcan A, Kocakaya B, Sahin C, Solmaz U. Sexual dysfunction in infertile Turkish females: prevalence and risk factors. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2014;30;182:128-31.
- 52. Aygin D & Eti Aslan F (2008) A study of sexual dysfunction in women with breast cancer. The Journal of Breast Health 4, 105-114.
- 53. Cayan S, Akbay E, Bozlu M, Canpolat B, Acar D, Ulusoy E. The prevalence of female sexual dysfunction and potential risk factors that may impair sexual function in Turkish women. Urologia Internationalis 2004;72, 52-57.
- 54. Castelo-Branco C, Blumel JE, Araya H, Riquelme R, Castro G, Haya J et al. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003; 23: 426-430.
- 55. Kadri N. Mchichi Alami KH, Mchakra Tahiri S. Women sexual dysfunction: a population-based epidemiological study. Arch Women Ment Health 2002; 5: 59-63.
- 56. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a primary care setting: a survey finding. The journal of sexual medicine. 2010 Sep 1;7(9):3080-7.
- 57. Hassanin IM, Helmy YA, Fathalla MM, Shahin AY. Prevalence and characteristics of female sexual dysfunction in a sample of women from Upper Egypt. International Journal of Gynecology & Obstetrics. 2010 Mar 1;108(3):219-23.
- 58. Bernhard LA. Sexuality and sexual health care for women. Clinical Obstetrics and gynecology. 2002 Dec 1;45(4):1089-98.
- 59. Onwujekwe DI, Ezechi OC, Ezeobi PM, Gbajabiamila TA. Incidence And Pattern Of Tuberculosis In HIV Infected Adult In Lagos Nigeria. NJCBR Online. 2017;7(9):23-8.
- 60. Kulchavenya E, Khomyakov V. Tuberculosis as a reason for male and female sexual dysfunction. Version: 2018-10-04. In: Bierklund Johansen TE, Wagenlehner FME, Matsumoto T, Cho YH, Krieger JN, Shoskes D, Naber KG, editors. Urogenital Infections and Inflammations. Berlin: German Medical Science GMS **Publishing** 2017-. House:
 - DOI: 10.5680/lhuii000041

447

448

449

450

451

452

453

454

455

456

457

458 459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477 478

479

480

481 482

483 484

485

486

487

- 61. Iwelunmor J, Ezechi O, Obiezu-Umeh C, Gbajabiamila T, Musa AZ, Oladele D, Idigbe I, Ohihoin A, Gyamfi J, Aifah A, Salako B. Capabilities, opportunities and motivations for integrating evidence-based strategy for hypertension control into HIV clinics in Southwest Nigeria. PloS one. 2019 Jun 6;14(6):e0217703.
- 62. Ogbera AO, Chinenye S, Akinlade A, Eregie A, Awobusuyi J. Frequency and correlates of sexual dysfunction in women with diabetes mellitus. The journal of sexual medicine. 2009 Dec 1;6(12):3401-6.
- 63. Schrooten W. Colebunders R. Youle M. Molenberghs G. Dedes N. Koitz G. Finazzi R. de Mey I. Florence E, Dreezen C, Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment, AIDS: May 25, 2001 - Volume 15 - Issue 8 - p 1019-1023

64. Martinez E, Collazos J, Mayo J. Sexual dysfunction with protease inhibitors. Lancet 1999, 353: 810 -

490 491 492

493

494

65. Goldmeier D, Kocsis A, Wasserman M. Sexual dysfunction in women with HIV. Sexually Transmitted Infections. 2005 Aug 1;81(4):284-.

Table 1. Sociodemographic characteristics of 2926 HIV-positive women in the study

Characteristics	No. of Respondents (%)		
Age (Years)			
• < 35	2007(68.6)		
• ≥ 35	919(31.4)		
Nigerian ethic Groups			
• Major ethnic groups (Igbo, H/Fulani, and	2218(75.8)		
Yoruba)			
 Ethnic minorities 	708(24.2)		
Education			
< Secondary	629(21.5)		
• ≥ Secondary	2296(78.5)		
Employment status			
 Working 	1741(59.5)		
 Not working 	1185(40.5)		
Marital status			
 Married 	1553(53.1)		
 Not married 	1372(46.9)		
Religion			
 Christianity 	2142(73.2)		
• Islam	711(24.9)		
• Others	73(2.5)		
Menopausal state			
 Premenopausal 	2494(85.2)		
 Postmenopausal 	432(14.8)		

Table 2. HIV-related characteristics of the 2926 respondents in the study

Characteristics	Frequency (%)
Time since HIV diagnosis (months)	
• < 120	1653(56.5)
• ≥ 120	1273(43.5)
CD4 counts (2867)	
• < 200	757(26.4)
• ≥ 200	2110(73.6)
 Median (SD) 	563 (194)
Viral load (2519)	
Not detected	1569(62.3)
 Detected 	950(37.7)
Partner HIV status (2448)	
• Negative	1065(43.5)
• Positive	1383(56.5)
HIV status Disclosure (2725)	
 Disclosed 	1807(66.3)
 Not disclosed 	918(33.4)
Type of antiretroviral therapy regimen	
NNRTI based	2051(70.1)
PI based	874(29.9)
Duration on ART (months)	
• < 96	1743(59.6)
• ≥96	1182(40.4)
 Median (SD) 	101(31)
Opportunistic infection (2525)	
• Yes	509(20.2)
• No	2016(79.8)
Co-morbid medical condition (2575)	
• Yes	564(21.9)
• No	2011(78.1)

Table 3: Distribution of 2926 respondents PHQ-9 total score

Total score	Number of Respondents (%)
5-9	2495(85.3)
10 – 14	313(10.7)
15 – 19	93(3.2)
≥ 20	25(0.8)
Range	0 - 25
Mean (SD)	5.6 (2.3)

Table 4. Distribution of domain-specific sexual dysfunction among the 2926 respondents in the study

Sexual Domains	Number of respondents with sexual
	dysfunction (%)
Desire	2247 (76.8)
Arousal	1931 (66.0)
Lubrication	1381 (47.2)
Orgasm	1463 (50.0)
Satisfaction	1135 (38.8)
Pain	1381 (47.2)

Table 5. Relationship between sociodemographic variables and sexual dysfunction among 2926 HIV-positive women in the study Table 6. Relationship between HIV-related variables and sexual dysfunction among 2926 HIV-positive women in the study

Variables	Sexual dysfunction	Normal sexual function N=837	Crude Odds Ratio (95% CI)	P value	Adjusted Odds Ratio (95% CI)	P value
	N= 2089					
• <35	1393(69.4)	614(30.6)	1.0		1.0	
• ≥35	696(75.7)	223(24.3.)	1.4(1.0 - 1.8)	0.04	1.1(0.8-1.5)	0.09
Education						
Secondary	447(71.1)	182(28.9)	0.9(0.7-1.14	0.51	-	_
• ≥ Secondary	1642(71.4)	655(28.6)	1.0		-	
Employment status						
 Working 	1253(72.0)	488(28.0)	1.1(0.8-1.4)	0.31	-	_
 Not working 	836(70.5)	349(29.5)	1.0		-	
Marital status						
 Married 	1062(68.4)	491(31.6)	0.5(0.4-0.7)	0.00	0.9(0.6-1.1)	0.05
 Not married 	1027(74.8)	346(25.2)	1.0		1.0	
Religion						
• Christianity	1525(71.2)	617(28.8)	1.0(0.7-1.3)	0.47	-	_
• Islam	504(70.9)	207(29.1)	1.0		-	
PHQ Score						
• <10	1723(69.1)	772(30.9)	1.0		1.0	
 ≥10 	366(84.9)	65(15.1)	2.5(1.6-4.0)	0.000	2.3(1.7 - 3.2)	0.000
Postmenopausal status	370(85.7)	62(14.3)	2.5(1.1 – 5.6)	0.013	2.0(1.4-4.1)	0.02
Co-morbid medical disorders	456(80.8)	108(19.2)	1.8(1.1 - 3.0)	0.02	1.8(1.4-2.7)	0.001
HIV Variables	Sexual dysfunction	Normal sexual function	Crude OR	P value	Adjusted OR	P value
	N=2089	N=837	(95% CI)		(95% CI)	
Time since HIV diagnosis (months)						
• < 120	1160(70.2)	493(29.8)	0.9(0.7-1.1)	0.18	_	_
120	1130(70.2)	175(=7.0)	0.5(0.7 1.1)	1 3.10		

• ≥ 120	929(72.9)	344(27.1)	1.0		-	
CD4 count						
• <200	560(74.0)	197(26.0)	1.8(0.6-3.1)	0.81	-	-
• ≥ 200	1529(72.5)	581(27.5)	1.0		-	
Viral load						
Not detected	1092(69.6)	477(30.4)	0.8(0.6-1.0)	0.1	-	-
Detected	590(62.1)	360(37.9)	1.0		-	
Partner HIV status						
 Positive 	1001(72.4)	383(27.6)	1.1(0.8 - 1.5)	0.60	-	-
• Negative	753(70.7)	312(29.4)	1.0		-	
HIV status disclosure						
 Disclosed 	1250(69.2)	557(30.8)	0.7(0.6 - 0.97)	0.04	0.7(0.6-0.8)	0.03
 Not disclosed 	692(75.4)	226(24.2)	1.0		1.0	
Antiretroviral drug regimen						
 NNRTI based 	135866.2)	693(33.9)	1.0	0.01	1.0	0.01
• PI Based	664(76.0)	210(24.0)	1.6(1.1 - 2.4)		1.3(1.2 - 2.1)	
Duration on HAART (month)				0.00		0.06
• < 96	1333(76.5)	410(23.5)	1.5(1.1-2.1)		1.4(0.9-2.4)	
• ≥ 96	801(67.8)	381(32.2)	1.0	0.01	1.0	0.07
Had opportunistic infection	401(78.8)	108(21.2)	1.6(1.1-2.4)		1.4(0.8-1.7)	

NNRTI: Nucleoside reverse transcriptase inhibitors; PI: Protease inhibitor